| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent developments signal a promising trajectory for product and service innovation, with a strategic focus on reorganization enhancing operational concentration. Key advancements, particularly in the oncology sector, showcase J&J's commitment to improving patient outcomes through new drug therapies. Moreover, the growth in the MedTech segment across specific sectors further underscores successful product enhancements. These efforts indicate a robust direction for ongoing product development and market leadership. |
| The price action of JOHNSON & JOHNSON (JNJ) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.4 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for JNJ since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.6, and the negative at -0.2 on 2025-10-19. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.6) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| JNJ | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-19 | 0%(0.1%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-10-18 | 0%(0.1%) | 0 | 0% | 0.4 | 3.5 | 7 | |||||||
| 2025-10-17 | 0%(0.1%) | 0 | 0% | 0.3 | 2.8 | -1 | |||||||
| 2025-10-16 | 0%(0.1%) | 0 | 0% | 0.3 | 2.7 | -1 | |||||||
| 2025-10-15 | 0%(0.1%) | 0 | 0% | 0.3 | 3 | 6 | |||||||
| 2025-10-14 | 1%(0.1%) | 0 | 0% | 0.3 | 2.9 | 5.3 | |||||||
| 2025-10-13 | 0%(0%) | 0 | 0% | -0.1 | 0.6 | -1 | |||||||
| 2025-10-12 | 0%(0%) | 0 | 0% | -0.1 | 0.7 | -1 | |||||||
| 2025-10-11 | 0%(0%) | 0 | 0% | -0.1 | 0.2 | -1 | |||||||
| 2025-10-10 | 0%(0%) | 0 | 0% | -0 | 0.9 | 5 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-10-19 17:01:11 The findings from this study indicate the broadening of treatment options for patients with specific cancer types, reflecting a growing landscape of personalized medicine in oncology. |
| 2025-10-19 17:01:11 The rapid and durable responses observed in patients suggest that the new treatment could significantly improve outcomes for individuals with difficult-to-treat cancers. |
| 2025-10-19 17:01:11 The article discusses the overall response rate of 45 percent, indicating an important metric in gauging the effectiveness of new drug therapies. |
| 2025-10-19 17:01:11 The active exploration of novel treatments in clinical trials points to a growing trend in the oncology sector focusing on innovative cancer management strategies. |
| 2025-10-19 17:01:11 The promising results of subcutaneous amivantamab in treating recurrent or metastatic head and neck cancer highlight its potential in cancer therapies, suggesting significant advancements in product development. |